-
4-[3-(4-hydroxyphenyl)-2-(phenylformamido)propanamido]benzoic acid
-
ChemBase ID:
404
-
Molecular Formular:
C23H20N2O5
-
Molecular Mass:
404.4153
-
Monoisotopic Mass:
404.13722175
-
SMILES and InChIs
SMILES:
O=C(Nc1ccc(cc1)C(=O)O)C(NC(=O)c1ccccc1)Cc1ccc(O)cc1
Canonical SMILES:
O=C(C(NC(=O)c1ccccc1)Cc1ccc(cc1)O)Nc1ccc(cc1)C(=O)O
InChI:
InChI=1S/C23H20N2O5/c26-19-12-6-15(7-13-19)14-20(25-21(27)16-4-2-1-3-5-16)22(28)24-18-10-8-17(9-11-18)23(29)30/h1-13,20,26H,14H2,(H,24,28)(H,25,27)(H,29,30)
InChIKey:
SPPTWHFVYKCNNK-UHFFFAOYSA-N
-
Cite this record
CBID:404 http://www.chembase.cn/molecule-404.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
4-[3-(4-hydroxyphenyl)-2-(phenylformamido)propanamido]benzoic acid
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
|
Synonyms
|
Bentiromide [USAN:BAN:INN:JAN]
|
Bentiromido [INN-Spanish]
|
Bentiromidum [INN-Latin]
|
BTPABA
|
PFD
|
PFT
|
Bentiromide
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
4.157471
|
H Acceptors
|
5
|
H Donor
|
4
|
LogD (pH = 5.5)
|
2.1798987
|
LogD (pH = 7.4)
|
0.47363257
|
Log P
|
3.5389557
|
Molar Refractivity
|
112.745 cm3
|
Polarizability
|
42.013195 Å3
|
Polar Surface Area
|
115.73 Å2
|
Rotatable Bonds
|
7
|
Lipinski's Rule of Five
|
true
|
Log P
|
2.99
|
LOG S
|
-4.99
|
Solubility (Water)
|
4.12e-03 g/l
|
PROPERTIES
PROPERTIES
Physical Property
Bioassay(PubChem)
Hydrophobicity(logP)
|
3.3
|
Show
data source
|
|
DETAILS
DETAILS
DrugBank
DrugBank -
DB00522
|
Item |
Information |
Drug Groups
|
approved |
Description
|
Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. It is given by mouth as a noninvasive test. The amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the U.S. or Canada (It was withdrawn in the US in October 1996). |
Indication |
Used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. |
Pharmacology |
Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. It is given by mouth as a noninvasive test. The amount of p-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the U.S. or Canada. |
Toxicity |
Symptoms of overdose include shortness of breath and troubled breathing. |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
Primarily hepatic. Enzymatic activity capable of hydrolyzing bentiromide has also been found in normal small intestine. |
References |
• |
Toskes PP: The bentiromide test for pancreatic exocrine insufficiency. Pharmacotherapy. 1984 Mar-Apr;4(2):74-80.
[Pubmed]
|
|
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent